Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Goserelin Acetate
Goserelin · 1 trial · 1 indication
Objective response rate to therapy (complete and partial responses) at 3 month intervals after beginning goserelin and pembrolizumab based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
| Arm | Type | Description |
|---|---|---|
| Goserelin Acetate + Pembrolizumab | EXPERIMENTAL | Goserelin Acetate, 3.6 mg, every four weeks, SQ Pembrolizumab, 200mg, every three weeks, IV |
| Name | Type | Description |
|---|---|---|
| Goserelin Acetate | DRUG | Goserelin Acetate, SQ, Q4W |
| Pembrolizumab | DRUG | Pembrolizumab, IV, Q3W |
Inclusion Criteria: * Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. * Age ≥ 18 years at the time of consent. * Locally advanced, recurrent, or metastatic salivary...
Goserelin is being studied for the treatment of advanced stage androgen receptor-positive salivary gland carcinoma. It is used as part of androgen deprivation therapy in combination with pembrolizumab in a Phase 2 clinical trial. The drug is administered to patients aged 18 years and older.
Goserelin targets the androgen receptor pathway by acting as a luteinizing hormone-releasing hormone agonist, which suppresses testosterone production. In the context of salivary gland carcinoma, this androgen deprivation is intended to inhibit tumor growth in androgen receptor-positive tumors. The drug is combined with pembrolizumab in the clinical trial.
Goserelin is developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical research on this drug for the treatment of salivary gland carcinoma.
Goserelin is in Phase 2 clinical development for the treatment of advanced stage androgen receptor-positive salivary gland carcinoma. It is an investigational drug in this indication and has not been approved by regulatory authorities for this use. The ongoing trial is active but not recruiting participants.
Goserelin is being evaluated in clinical trial NCT03942653, titled "Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma." This Phase 2 trial is active but not recruiting, with an enrollment of 20 participants in the United States.
Yes, Goserelin is also known as Goserelin Acetate. The drug is referred to by both names in clinical and research contexts. In the clinical trial for salivary gland carcinoma, it is used as part of androgen deprivation therapy in combination with pembrolizumab.